Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Other EventsItem 8.01.
On February 23, 2017, Titan Pharmaceuticals, Inc. (the “Company”) was advised by Mr. Eurelio Cavalier that he will be retiring from the Company’s board of directors at the end of the month. Mr. Cavalier has been an invaluable member of the board for over 18 years and the Company wishes him a happy retirement.
About Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura. The Company’s drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson’s disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Recent Trading Information
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) closed its last trading session up +0.10 at 3.75 with 92,712 shares trading hands.